BNP Testing for the Evaluation of Acute Dyspnea

Diagnostic Indication and Interpretation Thresholds

BNP testing is ordered to rule in or rule out acute heart failure when the initial clinical assessment (history, physical exam, chest radiograph) is equivocal. [American College of Cardiology] [@2][@3][@4]
BNP < 100 pg/mL effectively excludes heart failure (negative predictive value ≈ 90 %). [American College of Cardiology] [@1][@2][@5]
BNP > 500 pg/mL strongly confirms heart failure as the cause of dyspnea (positive likelihood ratio ≈ 6). [American College of Cardiology] [@1][@5]
BNP 100–500 pg/mL represents a gray zone; heart failure remains possible and alternative diagnoses (e.g., chronic left‑ventricular dysfunction, pulmonary embolism, lung disease) must be considered alongside clinical context. [American College of Cardiology] [@6][@7]

BNP measurement yields an overall diagnostic accuracy of 81–83 % for identifying heart failure, surpassing standard clinical judgment alone. [American College of Cardiology] [@3][@4]
When combined with clinical assessment, BNP improves the area under the receiver‑operating‑characteristic curve to 0.904, indicating significantly higher diagnostic performance. [American College of Cardiology] [@6]

Use of BNP in the emergency setting shortens time to discharge (median 8 days vs 11 days) and reduces total treatment costs (≈ $5,400 vs $7,300). [American College of Cardiology] [@5]
BNP testing facilitates the identification of alternative diagnoses (e.g., chronic obstructive pulmonary disease), helping to avoid unnecessary heart‑failure‑specific therapy. [American College of Cardiology] [@5]

Do not order BNP when heart failure is clinically obvious; routine testing in clear‑cut cases adds no value and wastes resources. [American College of Cardiology] [@2]
Do not use BNP as a substitute for echocardiography or to quantify the degree of left‑ventricular dysfunction. [American College of Cardiology] [@2]

In patients with renal impairment (GFR < 60 mL/min), BNP levels are often elevated; a higher cut‑off (> 200 pg/mL) should be applied to rule out heart failure. [American College of Cardiology] [@6][@8]
Advanced age, female sex, pulmonary disease, pulmonary embolism, sepsis, and malignancy can raise BNP independently of heart failure. [American College of Cardiology] [@6][@8][@7]
Right‑ventricular dysfunction (e.g., from pulmonary hypertension or acute pulmonary embolism) also elevates BNP. [European Society of Cardiology] [@10]
Obesity (BMI > 35 kg/m²) markedly lowers BNP, potentially producing false‑negative results even when heart failure is present. [American College of Cardiology] [@6][@7]
Flash pulmonary edema may present with a normal BNP because insufficient time has elapsed for ventricular release of the peptide. [American College of Cardiology] [@1][@6][@7]

Elevated BNP independently predicts mortality, heart‑failure hospitalization, and adverse cardiovascular events in patients presenting with dyspnea. [American College of Cardiology] [@6][@10]
BNP > 500 pg/mL (or NT‑proBNP > 900 pg/mL) identifies a high‑risk cohort that warrants more intensive monitoring and therapeutic escalation. [American College of Cardiology] [@1]
In the context of acute coronary syndromes, BNP adds prognostic information beyond troponin, improving risk stratification. [European Society of Cardiology] [@10]

< 100 pg/mL → heart failure unlikely; pursue alternative diagnoses. [American College of Cardiology] [@1][@5]
100–500 pg/mL → gray zone; integrate with clinical findings and consider echocardiography. [American College of Cardiology] [@6][@7]
> 500 pg/mL → heart failure very likely; initiate guideline‑directed therapy and obtain echocardiography. [American College of Cardiology] [@1][@6]